Abstract
Hypoxia is a phenomenon often arising in solid tumours, linked to aggressive malignancy, bad prognosis and resistance to therapy. Hypoxia-inducible factor-1 has been identified as a key mediator of cell and tissue adaptation to hypoxic conditions through transcriptional activation of many genes involved in glucose metabolism and other cancer-related processes, such as angiogenesis, cell survival and cell invasion. Cyclic adenosine 3′5′-monophosphate is one of the most ancient and evolutionarily conserved signalling molecules and the cAMP/PKA signalling pathway plays an important role in cellular adaptation to hypoxia. We have investigated possible new mechanisms behind hypoxic activation of the cAMP/PKA pathway. For the first time, we have shown that hypoxia induces transcriptional up-regulation of the system of adenylyl cyclases, enzymes responsible for cAMP production, in a panel of carcinoma cell lines of various origin. Our data prove functional relevance of the hypoxic increase of adenylyl cyclases VI and VII at least partially mediated by HIF-1 transcription factor. We have identified adenylyl cyclase VI and VII isoforms as mediators of cellular response to hypoxia, which led to the elevation of cAMP levels and enhanced PKA activity, with an impact on cell migration and pH regulation.
Introduction
Hypoxia is a characteristic feature of a broad range of solid tumours. Activation of the hypoxic pathway, due to an inadequate supply of oxygen, is associated with aggressive malignancy, poor prognosis and resistance to therapy. Hypoxia-inducible factor-1 (HIF-1) has been identified as a master regulator of cell and tissue adaptation to hypoxic conditions through transcriptional activation of many genes involved in glucose metabolism and other cancer-related processes, such as angiogenesis, cell survival and cell invasion1.
Carbonic anhydrase IX (CA IX) is a HIF-1-induced metalloenzyme associated with solid tumours2, 3. Its activity results in the neutralisation of intracellular pH necessary for tumour cell survival and in the extracellular acidification supporting invasiveness4, 5. Due to its pro-survival and pro-migratory effects, CA IX is recognised as an indicator of poor prognosis with a clinical potential6–8. Our previous study on MDCK cells transfected with CA IX revealed that hypoxia regulates both expression and activity of CA IX5, and that the intact intracellular tail is critical for proper functioning of CA IX9. Our recent study revealed that phosphorylation of Thr443 residue in the intracellular tail by the cyclic adenosine 3′5′-monophosphate (cAMP)-dependent protein kinase A (PKA) is required for CA IX activation10. Increased expression and activation of PKA has been associated with cancer and linked to tumour hypoxia, which up-regulates expression of its catalytic, as well as regulatory subunits in a HIF-1 dependent manner11. Importantly, hypoxia can also enhance PKA activity by increasing the intracellular concentration of cAMP.
Cyclic adenosine 3′5′-monophosphate is one of the most ancient and evolutionarily conserved signalling molecules12. In mammals, cAMP is present in every cell type and organ where it controls a wide range of cellular processes and functions. However, cAMP signalling also participates in several pathologic processes, e.g. cancer, neurodegeneration, heart failure and diabetes13. Intracellular levels of cAMP are regulated by the balance between the activities of two enzyme families: adenylyl cyclases, which control cAMP production, and phosphodiesterases, which control its degradation.
cAMP is synthesised from adenosine triphosphate by adenylyl cyclases (ADCY) that are encoded by ten various genes (ADCY 1-10). Nine members of them belong to the transmembrane subfamily (tmADCY, encoded by ADCY 1-9). They share a common structural organisation and possess a conserved catalytic mechanism14, 15. Cellular distribution and specific functions result from diverse mechanisms of their activation and inhibition. A pivotal role in their activation is played by heterotrimeric G proteins transducing multiple extracellular signals through G protein-coupled receptors. However, they also receive signals e.g. from PKA, protein kinase C, calmodulin, calcineurin and various small molecules. Second intracellular source of cAMP, soluble adenylyl cyclase (sADCY, encoded by ADCY 1 0), has no membrane spanning motifs and is localised within the cytosol, especially in mitochondria and nucleus16. sADCY is uniquely regulated by the intracellular bicarbonate17 and calcium18, and is insensitive to G protein-mediated regulation.
Recent research focused on cAMP brought a new perspective on its cellular distribution and associated signalling. The original model assumed cAMP generation at the plasma membrane and its diffusion through the cytoplasm in order to carry out cellular responses. Modern methods based on in situ measurements revealed its restricted diffusion inside signalling microdomains at the plasma membrane and other intracellular sites where cAMP is formed, degraded and localised closer to the place of action with the entire machinery of a unique composition, made up of ADCYs, phosphodiesterases (PDEs), A-kinase anchor proteins (AKAPs) and effector molecules, such as exchange proteins directly activated by cAMP (EPACs) and PKA19–21.
Hypoxic activation of the cAMP/PKA signalling pathway plays an important role in cell adaptation to hypoxia. As hypoxia is a phenomenon often occurring in tumours, we have studied the hypoxia-driven mechanisms behind the elevation of cAMP levels. We have especially focused on the transcriptional activation of adenylyl cyclases in hypoxia and on a possible participation of hypoxia-inducible factor-1 in this process.
Results
Hypoxia increases cAMP production despite higher activity of phosphodiesterases
Our previous observation indicated an elevated cAMP concentration in canine kidney epithelial MDCK cells during hypoxia10. The analysis of a panel of carcinoma cell lines (HeLa, C33a, RKO, and MCF7) cultured in normoxia (21% O2) and hypoxia (2% O2, 2% H2, 5%CO2, 91% N2) confirmed this finding. cAMP production was significantly increased in all tested cell lines (Fig. 1A). However, duration and strength of intracellular signalling mediated through cAMP is highly affected by the action of phosphodiesterases (PDEs). These enzymes degrade cAMP and catalyze its hydrolysis to AMP22, thus regulating various physiological processes. As PDEs are critical down-regulators of intracellular cAMP concentrations, we determined their enzymatic activity that could be behind the hypoxic elevation of cAMP. However, three cancer cell lines showed an increased PDE activity after 24 h incubation in hypoxia, and PDE activity in MCF7 was unchanged (Fig. 1B).
Hypoxia contributes to up-regulation of adenylyl cyclases at transcriptional level
In our study we have focused on investigating a possible direct transcriptional regulation of adenylyl cyclases by hypoxia in selected cancer cell lines, which could contribute to the elevation of cAMP. We analysed hypoxic mRNA profile of all ten ADCY genes. As expected, carcinoma cells of various origin exhibited slightly different transcriptional patterns. The most abundant isoforms present in all studied cell lines were isoforms 3, 6, and 7, and were therefore considered further (Fig. 2A). To elucidate a link between increased cAMP and mRNA levels of some adenylyl cyclases and hypoxia, we performed detailed in silico promoter analysis using MatInspector software (www.genomatix.de). We focused on binding motifs of hypoxia-responsive transcription factors including HIF-1 binding sites (HRE) in the isoforms abundantly present in all our studied cell lines in hypoxia. The software predicted HIF-1 binding sites in the regulatory regions of genes encoding ADCY6, ADCY7 (Fig. 2B), whereas the ADCY3 promoter did not show any HRE element. The comparison of mRNA levels of ADCY6 and ADCY7 in normoxic versus hypoxic samples revealed their increased hypoxic transcription in all four cancer cell types (Fig. 2C), whereas ADCY3 was unchanged or reduced.
Protein levels of ADCY VI and ADCY VII are increased in hypoxia in a HIF-1 dependent manner
Changes in the expression of ADCY VI and ADCY VII in normoxic versus hypoxic RKO cells were proved also at protein levels by Western blotting (Fig. 3A). These results were verified by flow cytometry analysis (Fig. 3B). The histogram of analysed cells showed increased intensity of adenylyl cyclase VI and VII signal in hypoxia. Averaged geometric mean of measured intensities from three independent experiments shifted toward higher values in hypoxia: by 59.9% ± 19.9% and 35.8% ± 13.3% for ADCY VI and VII, respectively. Immunofluorescent analysis of RKO cells cultured in normoxic and hypoxic conditions (2% O2) for 24 h also confirmed a significant increase at the protein level of both ADCY VI and ADCY VII isoforms (Fig. 3C). Average intensity of immunofluorescent signal from three independent experiments per pixel increased in hypoxia by 10.1 ± 4.1% and 11.5 ± 4.7% for ADCY VI and VII. As in silico analysis predicted the involvement of HIF-1 transcription factor in the hypoxic elevation of the ADCY isoforms amounts, we used transient silencing of the HIF-1α subunit to verify a possible role of HIF-1 in this process. Results showed reduced mRNA (Fig. 3D) and protein levels of ADCY VI and ADCY VII in hypoxic RKO cells after HIF-1α silencing (Fig. 3E). The suppression of HIF-1α in RKO cells also considerably reduced the concentration of cAMP in hypoxia as detected by immunofluorescent staining (Fig. 3F) and also verified by ELISA (Fig. 3G). Obtained data support the role for HIF-1 as a possible transcriptional regulator of these ADCYs during hypoxia. Thus, it appears that hypoxia can control an important step of cAMP generation through HIF-1α also at the level of adenylyl cyclases expression.
Suppression of ADCY6 and ADCY7 during hypoxia leads to down-regulation of cAMP/PKA signalling
Transient silencing of ADCY6 and ADCY7 was used to assess their contribution to the hypoxic elevation of cAMP (Fig. 4A). After their suppression, we detected a significant reduction of cAMP signal (Fig. 4B,C). Similarly, levels of phospho-substrates of PKA were decreased in hypoxia after silencing of both ADCY isoforms (Fig. 4D). These data prove functional consequences of suppressing ADCY6 and ADCY7 for PKA activity in hypoxia. Reduction in the phosphorylation status of PKA substrates was considerably higher when RKO cells were subjected to shRNA targeting of HIF-1α (data not shown). This is in agreement with the previous evidence denoting HIF-1 as a regulator of hypoxic activation and expression of PKA11. The effect of ADCY6 and ADCY7 suppression on cAMP signalling during hypoxia was confirmed by luciferase assay in which the activity of CRE reporter was reduced significantly by almost 20% (Fig. 4E).
Suppression of ADCY6 and ADCY7 affects migration capacity of hypoxic cells
There is mounting evidence that PKA is an important regulator of cell migration through phosphorylation and activation of several components of the pH-regulating machinery11, 23. These include Na+/H+ exchanger 124, 25 and CA IX10, 26 which contribute to intracellular alkalinisation and extracellular acidification at the leading front area of migrating cells. In agreement with this evidence, we found that silencing of ADCY6 and ADCY7 genes resulted in reduced acidification of the culture medium of hypoxic RKO cells when compared to scramble control (∆pH~0.2, Fig. 5A). This indicated a possible contribution of hypoxia-up-regulated ADCY isoforms in PKA activation. To further assess functional relevance of thus affected PKA activation we performed a wound healing assay. Results showed a decreased migration rate of RKO cells after suppression of ADCY6 and ADCY7 (Fig. 5B,C) supporting our assumptions. The migration was slowed to 74.2 ± 8.8% and 82.9 ± 6.4% of the control samples after silencing of ADCY 6 and 7, respectively (mean ± stdev of three independent experiments).
Discussion
Cyclic adenosine 3′5′-monophosphate is one of the most ancient and evolutionarily conserved signalling molecules responding to various stimuli and controlling diverse range of cellular processes. Different receptors are responsible for cAMP accumulation in cells that causes different physiological outcomes. In humans, the cAMP synthesis from ATP is mediated by nine transmembrane adenylyl cyclases and one soluble isoform. In hypoxia, the cAMP/PKA signalling pathway plays an important role in cells adaptation to oxygen insufficiency. During hypoxia, changes in cAMP levels increase PKA activation and enhanced expression of PKA subunits occurs. PKA directly contributes to tumour biology, particularly to hypoxia-mediated invasion and migration11. Moreover, PKA directly cooperates with a key regulator of molecular responses to hypoxia. Bullen et al. demonstrated that PKA phosphorylated Thr63 and Ser692 on HIF-1α and thus inhibited its proteosomal degradation in HeLa carcinoma cells and rat cardiomyocytes27. PKA also stimulated the binding of the coactivator p300 to HIF-1α and enhanced HIF-1α transcriptional activity and target gene expression. In this manner, PKA influences a panel of molecules induced by hypoxia, some of them also via direct phosphorylation (e.g. Thr443 of carbonic anhydrase IX10). Furthermore, increased cAMP concentrations enhanced the expression of HIF target gene encoding CD73, an enzyme that converts extracellular adenosine 5′-triphosphate to adenosine28, 29. Release and extracellular accumulation of adenosine is one of the many adaptive mechanisms that have evolved as a protective response to hypoxia30, 31. This molecule participates in the optimal functioning of hypoxic tissues and mediates numerous metabolic effects32. Moreover, hypoxia also increases expression of A2A and A2B subtypes of adenosine receptors33, 34. In this manner adenosine signal can be transmitted through G stimulatory proteins and enhance activation of adenylyl cyclases, enzymes responsible for cAMP generation.
In our study, we have proved hypoxia-mediated increase in cAMP levels in various cancer cells in vitro (Fig. 1A). However, it is known that duration and strength of intracellular signalling mediated through cAMP is highly affected by the action of phosphodiesterases (PDEs). Eleven PDE families have been identified, among them cAMP specific isoforms (PDE 4, 7, 8) or members with dual specificity also for cyclic guanosine monophosphate (PDE 1, 2, 3, 10, 11). PDEs degrade cAMP and catalyze its hydrolysis to AMP22, thus regulating various physiological processes. Changes in their expression or enzyme activity have been associated with various pathologies including cancer35. As PDEs are critical down-regulators of intracellular cAMP concentrations we also determined their enzyme activity that could be behind hypoxic elevation of cAMP. Our results showed an increased or unchanged PDE activity after 24 h incubation in hypoxia in various cancer cell lines (Fig. 1B). In fact, this observation was in line with the recent report that hypoxia can induce expression of PDE 4 isoform36. Therefore, phosphodiesterase activity cannot be behind the mechanism responsible for elevated levels of cAMP in hypoxia. Moreover, intracellular cAMP levels may also be affected by its efflux into the extracellular space mediated by multidrug resistance proteins belonging to the ABC transporter superfamily37, 38. However, measurement of cAMP in culture medium from normoxic versus hypoxic HeLa and C33a cells using ELISA method revealed no significant changes in either cell line (data not shown).
Further, we have focused on the transcriptional activation of adenylyl cyclases in hypoxia and on its possible participation in hypoxic activation of the cAMP/PKA pathway. For the first time, we showed that hypoxia induces transcriptional up-regulation of adenylyl cyclases 6 and 7 in a panel of carcinoma cell lines of various origin (Fig. 2C). Our data prove functional relevance of hypoxic increase of adenylyl cyclases VI and VII at least partially mediated by the HIF-1 transcription factor (Fig. 3D,E). HIF-1α is a key transcription factor controlling responses to hypoxia. In addition, various transcription factors e.g. SP1/SP3, NFκB, CREB, AP1, p53, Egr1, Ets, Smad etc. are also induced in hypoxia and have been demonstrated to be hypoxia-responsive39. All together they contribute to the transcriptional machinery activated by this important pathophysiological stimulus supporting processes such as tumour development. Due to the increased cAMP levels (Fig. 1A) and mRNA and protein levels of adenylyl cyclases VI and VII (Figs 2C, and 3A,B,C) as a consequence of hypoxia, we have performed in silico promoter analysis using MatInspector software. This analysis predicted potential HIF-1 binding sites in the regulatory regions of both ADCY6 and ADCY7 genes (Fig. 2B). Moreover, analysis showed also abundant occurrence of above-mentioned hypoxia-associated transcription factor binding elements, located upstream as well as downstream to the transcription start sites.
To date, only ADCY7 has been linked to hypoxic up-regulation at both transcriptional and protein levels in a mouse model of hypoxia-induced retinopathy40. We used Genevestigator tool (https://genevestigator.com/gv/) to analyze the expression of adenylyl cyclases comparing normal and hypoxic samples. Only a small number of Genevestigator datasets is available for such search. They revealed that only ADCY7 out of all ten isoforms was detected as an up-regulated gene in two independent hypoxic studies. Both breast and pancreatic carcinoma cells showed two-fold elevation in hypoxic samples compared to normoxia. In both studies ADCY7 correlated with HIF-1-induced tumor-associated carbonic anhydrase 9.
Moreover, comparison of tumour versus normal tissues samples across Genevestigator, Oncomine (www.oncomine.org) and Expression Atlas (http://www.ebi.ac.uk/) databases showed up-regulation of the ADCY7 gene mostly in renal, breast, pancreas, gastric, ovarian cancer and hepatocellular carcinoma in several microarray and RNA-sequencing studies (Fig. 6A). Recent research also indicates differences between 2D and 3D cell cultures. Databases work with clinical samples which may represent the tumour environment which is different from hypoxic 2D culture. All these reasons could be behind difficulties in detecting ADCY6 up-regulation in real tumour samples although there are couple of studies showing up-regulation of ADCY6 in tumour compared to normal tissues (e.g. osteosarcoma, prostate adenocarcinoma, pancreatic ductal adenocarcinoma and bladder cancer) (Fig. 6B).
Our findings support the view that hypoxia induces the cAMP signalling pathway at several upstream and downstream levels. We suggest that up-regulation of adenylyl cyclases participates in the hypoxia-induced elevation of intracellular cAMP. In these processes HIF-1 seems to play an important role and to contribute also to an increased expression of isoforms ADCY VI and ADCY VII, resulting in higher cAMP generation that affects PKA function, with impact on cell migration and pH regulation.
cAMP represents a molecule of interest which also plays a role in the process of tumorigenesis, particularly by being a part of tumour cells adaptation to reduced oxygen levels reported in carcinoma.
Materials and methods
Cell culture
HeLa and C33a cervical carcinoma cells, RKO colorectal carcinoma cells and MCF7 breast carcinoma cells were cultured under standard conditions in Dulbecco’s modified Eagle’s medium supplemented with 10% foetal calf serum (Bio Whittaker) and gentamicine (Sandoz) in humidified air containing 21% O2, 5% CO2 at 37 °C and in hypoxic conditions at anaerobic workstation (2% O2, 2% H2, 5%CO2, 91% N2, Ruskinn Technology). All cell lines were purchased from ATCC and regularly tested for Mycoplasma contamination.
cAMP assay
Cell lysates were prepared using RIPA lysis buffer (1% Triton X-100 and 1% deoxycholate in PBS) and diluted in PBS to concentration 0.5 μg/μl. 100 μl of protein samples were loaded onto 96 well plate (high binding microlon 600, ref. 655061, Greiner bio-one) in triplicates and incubated at 37 °C overnight. The following day samples were washed with 0.02% Tween-20 in PBS, blocked with 10% FCS in wash buffer for 1 h, incubated with anti-cAMP antibody (1 μg/ml) for 3 h, washed again and incubated with HRP-conjugated secondary antibody for 1 h. All steps were performed at room temperature. Absorbance and colour changes after development with orthophenylene diamine were measured at 492 nm. Three independent biological experiments were performed, each in triplicates. Alternatively, detection of cAMP level was performed with commercial kit (ref. 4339 Cell Signaling) according to manufacturer’s instructions. Two independent biological experiments were performed, each in triplicates.
PDE activity assay
Activity of phosphodiesterases was determined using the PDELight Assay kit (Lonza). 20 μl of cell lysates prepared using RIPA lysis buffer were analysed according to the manufacturer’s instructions. Three independent biological experiments were performed, each in triplicates.
Transient transfection
The cells were plated onto 30-mm Petri dishes to reach approximately 70% monolayer density on the following day. Transfection was performed with 2 μg of the plasmid (pSuper_shCtrl, pSuper_shHIF-1α) or with 25 nM siRNA (Thermo Scientific, non-targeting control pool D-001810-10, On-TARGETplus SMART pool human ADCY6_L-006636-00 and ADCY7_L-006801-00) using 2 μl Attractene transfection reagent (Qiagen). For luciferase reporter assay, transfection was performed with 1 μg of the luciferase reporter plasmid containing cAMP response elements (Affymetrix), 50 ng of pRL-TK renilla vector (Promega) and 25 nM siRNA using 2,5 μl Attractene transfection reagent according to the manufacturer’s recommendations. After 24 h, the transfected cells were trypsinised, plated according to the type of further experiment, allowed to attach and cultured in normoxia and hypoxia for 24 h.
RT PCR and quantitative (q) PCR
Total RNA was isolated using Trizol solution (Sigma) and reverse transcription of 3 μg RNA for each sample was performed with the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) according to the manufacturer’s recommendations. Semiquantitative RT PCR was carried out using Dream Taq Green PCR Master mix (Thermo Scientific). Each PCR reaction contained 5 μl of 10x diluted cDNA and ran for 3 min at 95 °C for initial denaturation followed by 30 cycles of 95 °C-60 °C-72 °C (all steps for 30 s) and final elongation at 72 °C for 5 min. Q-PCR was carried out using Maxima Syber Green PCR Master mix (Thermo Scientific) and ran for 10 min at 95 °C for initial denaturation followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Sample Ct values were normalised to actin. Relative expression was calculated using the ΔΔCt method. All amplifications were performed in triplicate. Results were calculated from three independent experiments. The bands for RT PCR were quantified in ImageJ software. All oligonucleotides used for RT PCR and q-PCR are as follows: ADCY1_S: 5′ccttttggtcaccttcgtgt3′, ADCY1_A: 5′ctcagtcagaatccgcacaa3′, ADCY2_S: 5′aacagcacctggtgaaaacc3′, ADCY2_A: 5′tgatcttgccgttctctgtg3′, ADCY3_S: 5′cattggcagcacgtatatgg3′, ADCY3_A: 5′gcgcagcatgaagttattga3′, ADCY4_S: 5′actgctgatgacccgttacc3′, ADCY4_A: 5′ccactgtttctgcgagttga3′, ADCY5_S: 5′ttcttcaacaacgggacctc3′, ADCY5_A: 5′cctgcagtttccagaggaag3′, ADCY6_S: 5′ggcagctggaaaagatcaag3′, ADCY6_A: 5′gcccaatcttcatctggaaa3′, ADCY7_S: 5′gagatgctgtcagccattga3′, ADCY7_A: 5′agcaggatgcagacgaagat3´, ADCY8_S: 5′caggtcatcctccaagtggt3′, ADCY8_A: 5′cgctcctgtctttggttctc3′, ADCY9_S: 5′cgctcaaggtctgaacttcc3′, ADCY9_A: 5′cggggtcaccagtacctaga3′, ADCY10_S: 5′cgttttccaacaaacggagt3′, ADCY10_A: 5′cgttggaggtgacaggtttt3′, HIF-1α_S: 5′gcttggtgctgatttgtgaacc3′, HIF-1α_A: 5´gcatcctgtactgtcctgtggtg3′, Actin_S: 5′ccaaccgcgagaagatgacc3′, Actin_A: 5′gatcttcatgaggtagtcagt3′.
Western blotting
Cells grown in confluent monolayers were rinsed twice with PBS, resuspended in ice-cold lysis buffer (1% Triton X-100; 50 mM Tris pH7.5; 150 mM NaCl; 0.5% Nonidet P-40) containing protease (Roche) and phosphatase inhibitors cocktail (Sigma Aldrich), disrupted by sonication and cleared by centrifugation. Protein concentrations were quantified using the BCA protein assay reagents (Pierce). The extracts (100 μg/lane) were resolved in 8% SDS-PAGE and transferred to a PVDF membrane (Macherey-Nagel). Protein bands were visualised using an enhanced chemiluminescence kit (GE Healthcare Bio-Sciences) and quantified in ImageJ software (using Analyze-Gels). All results were normalised to actin.
Immunofluorescence
RKO cells grown on glass coverslips for 24 h in hypoxia were fixed in 4% paraformaldehyde at room temperature for 20 min and permeabilised with 0.02% Tween-20 in PBS. After blocking in 3% BSA in PBS for 1 h, the cells were incubated with primary antibody against cAMP, ADCY VI or ADCY VII overnight at 4 °C. The following day, the cells were washed four times for 10 min with 0.02% Tween-20 in PBS, incubated for 1 h at 37 °C with Alexa-conjugated secondary antibody, and washed three times with PBS. Finally, the cells were mounted in Fluoroshield Mounting Medium with DAPI (Abcam) and analysed by laser scanning microscopy (LSM 510 Meta Microscope; Zeiss, objective 40x). The staining of all samples was performed under the same conditions. All immunofluorescent images were acquired at the same microscope settings for all compared samples.
Quantification of cAMP fluorescent signal
Images of cells with fluorescent cAMP signal were processed in the ImageJ software. Intensity of grayscale images reflected cAMP amount, the brighter pixels meaning higher levels of cAMP. Images were thresholded according to their intensity to exclude pixels with background only. Only pixels with the cAMP signals were analysed, and the average intensity per pixel was calculated for cAMP signal for normoxic and hypoxic cells, or cells with silenced HIF-1α, ADCY6 or ADCY7. At least 200 cells were processed for each sample. Results were calculated from three independent biological experiments.
Flow cytometry analysis (FACS)
RKO cells were cultured under normoxic and hypoxic conditions. After 24 h, the cells were detached using trypsin, resuspended in 1% FCS in PBS. After centrifugation, the cells were fixed in ice-cold 70% ethanol for 30 min at 4 °C, centrifuged and washed twice with 1% FCS in PBS. For measurement of the expression of ADCY VI and ADCY VII, the cells were incubated with primary antibodies overnight at 4 °C. After incubation, the cells were centrifuged, washed twice and incubated with secondary antibody for 1 h at 4 °C, and then washed four times. Cells stained with secondary antibody only were used as negative control. The samples were analysed using a Guava EasyCyte Plus flow cytometer (Millipore) with FCS Express software. The staining of all samples was performed under the same conditions. Geometric mean of measured intensities was calculated from three independent experiments.
pH measurement
pH of cell culture media was measured by a special microelectrode (Mettler Toledo, InLab® Micro) designed for measurement in small volumes. The measurement by the electrode was done directly in the hypoxic workstation under the oxygen concentration of 2%. The graph in Fig. 5A gives the difference between pH of the culture medium of cells with silenced ADCY isoforms and medium of control cells. Data are presented as mean ± stdev of three independent experiments.
Wound healing assay
RKO cells transfected with siADCY6, siADCY7 and non-targeting siRNA control (siCtrl), were seeded to confluence on tissue culture plates 24 h post transfection. Cells were left to attach, moved into hypoxic workstation and cultured for 24 h in 2% O2. As a next step, the cells were starved in DMEM with 0.5% FCS for 6 h in 2% O2. A wound was made with a sterile micropipette tip. Floating cells were removed by washing with PBS. Fresh DMEM with 0.5% FCS and hepatocyte growth factor (HGF, 5 ng/ml, Sigma) was then added. Time-lapse acquisition was performed at Zeiss Cell Observer System at magnification 100x, in the incubation chamber at 37 °C in 2% O2 and 5% CO2 atmosphere. Imaging was managed by Axiovision 4.8 software, using the Multidimensional Acquisition settings. We evaluated the movement of the migrating fronts of cells covering the wound for at least 10 positions (for each sample). Positions were selected at a sufficient distance from each other and their fields of view never overlapped. Wound healing was quantified using ImageJ software as the wound area covered by cells in 12 h and results were compared by t-test. The assay was repeated three times.
Antibodies
Primary antibodies: mouse monoclonal anti-human HIF-1α (1:250, ref. 610959 BD Transduction Laboratories); goat polyclonal anti-human actin (1:1000, ref. sc1615 Santa Cruz Biotechnology); in house mouse monoclonal anti-human carbonic anhydrase IX- M75 hybridoma medium (1:3); rabbit polyclonal anti-human ADCY VI (1:250 in WB, ref. SAB2100054 Sigma); rabbit polyclonal anti-human ADCY VI (1:50 in IF and FACS, ref. sc25500 Santa Cruz Biotechnology); goat polyclonal anti-human ADCY VII (1:500 in WB, ref. sc32120 Santa Cruz Biotechnology), rabbit polyclonal anti-human ADCY VII (1:50 in IF and FACS, ref. SAB1303163 Sigma); rabbit monoclonal anti-human phospho-PKA substrates (1:1000, ref. 100G7E Cell Signaling); mouse monoclonal anti- cAMP (ref. ab24851 Abcam). Secondary antibodies: Alexa Fluor 488-conjugated donkey anti-mouse IgG; Alexa Fluor 488-conjugated donkey anti-rabbit IgG; (both 1:1000, Invitrogen); HRP-conjugated goat anti-mouse IgG (1:5000 in Western blotting, 1:2000 in ELISA, Dako); HRP-conjugated rabbit anti-goat IgG (1:5000, Dako); HRP-conjugated goat anti-rabbit IgG (1:5000, Dako).
Acknowledgements
This work was supported by the grants APVV-0893-11, Biomed ITMS 26240220087, VEGA 2/0081/14 and VEGA 2/0133/16. shRNA targeting human HIF-1α cloned in pSuper plasmid was kindly provided by Dr. Nicholas Denko, Department of Radiation Oncology, Ohio State University Wexner Medical Center, Columbus, Ohio.
Author Contributions
J.P.* conceived the study; J.P. and L.C. supervised the study; J.P., V.S. and L.C. designed experiments; V.S., L.C., A.S., M.L., P.R., F.I., M.B. performed experiments; V.S. and L.C. analysed data and wrote the manuscript, J.P. and S.P. made manuscript revisions. *senior scientist.
Competing Interests
The authors declare that they have no competing interests.
Footnotes
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–732. doi: 10.1038/nrc1187. [DOI] [PubMed] [Google Scholar]
- 2.Chiche J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009;69:358–368. doi: 10.1158/0008-5472.CAN-08-2470. [DOI] [PubMed] [Google Scholar]
- 3.Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des. 2008;14:685–698. doi: 10.2174/138161208783877893. [DOI] [PubMed] [Google Scholar]
- 4.Pastorekova S, Ratcliffe PJ, Pastorek J. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int. 2008;101(Suppl 4):8–15. doi: 10.1111/j.1464-410X.2008.07642.x. [DOI] [PubMed] [Google Scholar]
- 5.Svastova E, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004;577:439–445. doi: 10.1016/j.febslet.2004.10.043. [DOI] [PubMed] [Google Scholar]
- 6.Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle. 2004;3:164–167. doi: 10.4161/cc.3.2.618. [DOI] [PubMed] [Google Scholar]
- 7.van Kuijk SJ, et al. Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Front Oncol. 2016;6 doi: 10.3389/fonc.2016.00069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zat’ovicova M, et al. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods. 2003;282:117–134. doi: 10.1016/j.jim.2003.08.011. [DOI] [PubMed] [Google Scholar]
- 9.Hulikova A, et al. Intact intracellular tail is critical for proper functioning of the tumor-associated, hypoxia-regulated carbonic anhydrase IX. FEBS Lett. 2009;583:3563–3568. doi: 10.1016/j.febslet.2009.10.060. [DOI] [PubMed] [Google Scholar]
- 10.Ditte P, et al. Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res. 2011;71:7558–7567. doi: 10.1158/0008-5472.CAN-11-2520. [DOI] [PubMed] [Google Scholar]
- 11.Shaikh D, et al. cAMP-dependent protein kinase is essential for hypoxia-mediated epithelial-mesenchymal transition, migration, and invasion in lung cancer cells. Cell Signal. 2012;24:2396–2406. doi: 10.1016/j.cellsig.2012.08.007. [DOI] [PubMed] [Google Scholar]
- 12.Rall TW, Sutherland EW. Formation of a cyclic adenine ribonucleotide by tissue particles. J Biol Chem. 1958;232:1065–1076. [PubMed] [Google Scholar]
- 13.Troger J, Moutty MC, Skroblin P, Klussmann E. A-kinase anchoring proteins as potential drug targets. Br J Pharmacol. 2012;166:420–433. doi: 10.1111/j.1476-5381.2011.01796.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. Science. 1997;278:1907–1916. doi: 10.1126/science.278.5345.1907. [DOI] [PubMed] [Google Scholar]
- 15.Zhang G, Liu Y, Ruoho AE, Hurley JH. Structure of the adenylyl cyclase catalytic core. Nature. 1997;386:247–253. doi: 10.1038/386247a0. [DOI] [PubMed] [Google Scholar]
- 16.Zippin JH, et al. Compartmentalization of bicarbonate-sensitive adenylyl cyclase in distinct signaling microdomains. FASEB J. 2003;17:82–84. doi: 10.1096/fj.02-0598fje. [DOI] [PubMed] [Google Scholar]
- 17.Chen Y, et al. Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. Science. 2000;289:625–628. doi: 10.1126/science.289.5479.625. [DOI] [PubMed] [Google Scholar]
- 18.Jaiswal BS, Conti M. Calcium regulation of the soluble adenylyl cyclase expressed in mammalian spermatozoa. Proc Natl Acad Sci U S A. 2003;100:10676–10681. doi: 10.1073/pnas.1831008100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Jurevicius J, Fischmeister R. cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci USA. 1996;93:295–299. doi: 10.1073/pnas.93.1.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 2002;295:1711–1715. doi: 10.1126/science.1069982. [DOI] [PubMed] [Google Scholar]
- 21.Zippin JH, et al. Bicarbonate-responsive “soluble” adenylyl cyclase defines a nuclear cAMP microdomain. J Cell Biol. 2004;164:527–534. doi: 10.1083/jcb.200311119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481–511. doi: 10.1146/annurev.biochem.76.060305.150444. [DOI] [PubMed] [Google Scholar]
- 23.Finger EC, et al. Hypoxic induction of AKAP12 variant 2 shifts PKA-mediated protein phosphorylation to enhance migration and metastasis of melanoma cells. Proc Natl Acad Sci USA. 2015;112:4441–4446. doi: 10.1073/pnas.1418164112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Cardone RA, et al. The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell. 2007;18:1768–1780. doi: 10.1091/mbc.E06-07-0617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Kandasamy RA, et al. Plasma membrane Na+/H+ exchanger isoforms (NHE-1, -2, and -3) are differentially responsive to second messenger agonists of the protein kinase A and C pathways. J Biol Chem. 1995;270:29209–29216. doi: 10.1074/jbc.270.49.29209. [DOI] [PubMed] [Google Scholar]
- 26.Svastova E, et al. Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem. 2012;287:3392–3402. doi: 10.1074/jbc.M111.286062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Bullen JW, et al. Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1. Sci Signal. 2016;9 doi: 10.1126/scisignal.aaf0583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Synnestvedt K, et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110:993–1002. doi: 10.1172/JCI0215337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Zimmermann H. 5′-Nucleotidase: molecular structure and functional aspects. Biochem J. 1992;285(Pt 2):345–365. doi: 10.1042/bj2850345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications. Circulation. 2001;104(part 2):3158–3167. doi: 10.1161/hc5001.100039. [DOI] [PubMed] [Google Scholar]
- 31.Marshall JM. The Joan Mott Prize Lecture. The integrated response to hypoxia: from circulation to cells. Exp Physiol. 1999;84:449–470. doi: 10.1111/j.1469-445X.1999.01884.x. [DOI] [PubMed] [Google Scholar]
- 32.Villarreal F, et al. Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects. Mol Cell Biochem. 2003;251:17–26. doi: 10.1023/A:1025401026441. [DOI] [PubMed] [Google Scholar]
- 33.Feoktistov I, et al. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension. 2004;44:649–654. doi: 10.1161/01.HYP.0000144800.21037.a5. [DOI] [PubMed] [Google Scholar]
- 34.Sitkovsky MV, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol. 2004;22:657–682. doi: 10.1146/annurev.immunol.22.012703.104731. [DOI] [PubMed] [Google Scholar]
- 35.Azevedo MF, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs) Endocr Rev. 2014;35:195–233. doi: 10.1210/er.2013-1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Millen J, MacLean MR, Houslay MD. Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells. Eur J Cell Biol. 2006;85:679–691. doi: 10.1016/j.ejcb.2006.01.006. [DOI] [PubMed] [Google Scholar]
- 37.Biondi C, et al. cAMP efflux from human trophoblast cell lines: a role for multidrug resistance protein (MRP)1 transporter. Mol Hum Reprod. 2010;16:481–491. doi: 10.1093/molehr/gaq023. [DOI] [PubMed] [Google Scholar]
- 38.Hofer AM, Lefkimmiatis K. Extracellular calcium and cAMP: second messengers as “third messengers”? Physiology (Bethesda) 2007;22:320–327. doi: 10.1152/physiol.00019.2007. [DOI] [PubMed] [Google Scholar]
- 39.Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch. 2005;450:363–371. doi: 10.1007/s00424-005-1413-7. [DOI] [PubMed] [Google Scholar]
- 40.Ristori C, et al. Adenylyl cyclase/cAMP system involvement in the antiangiogenic effect of somatostatin in the retina. Results from transgenic mice. Neurochem Res. 2008;33:1247–1255. doi: 10.1007/s11064-007-9576-6. [DOI] [PubMed] [Google Scholar]